[{"id":"405369f8-6c34-4eaf-86cd-9b205b8bd8af","acronym":"ETCTN 10183","url":"https://clinicaltrials.gov/study/NCT03854474","created_at":"2021-01-18T19:01:24.885Z","updated_at":"2025-02-25T15:18:02.909Z","phase":"Phase 1/2","brief_title":"Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma","source_id_and_acronym":"NCT03854474 - ETCTN 10183","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • PD-1","pipe":" | ","alterations":" EZH2 mutation","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EZH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • Tazverik (tazemetostat) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/18/2019","start_date":" 11/18/2019","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-12"},{"id":"354295c1-22c1-46a8-9795-aed719694630","acronym":"","url":"https://clinicaltrials.gov/study/NCT05942300","created_at":"2023-07-12T15:08:55.008Z","updated_at":"2025-02-25T15:28:10.507Z","phase":"Phase 1","brief_title":"CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer","source_id_and_acronym":"NCT05942300","lead_sponsor":"Lan Coffman","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • tulmimetostat (DZR123)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/10/2024","start_date":" 01/10/2024","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2025-02-11"},{"id":"64837254-ecf8-44d3-8267-0595bd882719","acronym":"","url":"https://clinicaltrials.gov/study/NCT05633979","created_at":"2022-12-01T15:57:19.166Z","updated_at":"2025-02-25T15:27:45.382Z","phase":"Phase 1","brief_title":"Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer","source_id_and_acronym":"NCT05633979","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • UGT1A1","pipe":"","alterations":" ","tags":["HER-2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • Ezharmia (valemetostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 02/09/2023","start_date":" 02/09/2023","primary_txt":" Primary completion: 12/31/2030","primary_completion_date":" 12/31/2030","study_txt":" Completion: 12/31/2032","study_completion_date":" 12/31/2032","last_update_posted":"2025-02-10"},{"id":"d2101305-ed21-4d8c-a684-029721d03d01","acronym":"NCI-2022-03215","url":"https://clinicaltrials.gov/study/NCT05353439","created_at":"2022-04-29T11:55:38.458Z","updated_at":"2025-02-25T16:26:50.630Z","phase":"Phase 1","brief_title":"Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer","source_id_and_acronym":"NCT05353439 - NCI-2022-03215","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Tazverik (tazemetostat) • topotecan • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Suspended","enrollment":" Enrollment 60","initiation":"Initiation: 07/27/2022","start_date":" 07/27/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2025-01-28"},{"id":"15a57807-96a4-44c8-8faf-02682afe4492","acronym":"VALYM","url":"https://clinicaltrials.gov/study/NCT04842877","created_at":"2021-04-13T13:30:33.989Z","updated_at":"2025-02-25T16:26:30.882Z","phase":"Phase 2","brief_title":"Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma","source_id_and_acronym":"NCT04842877 - VALYM","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" SLC1A5","pipe":" | ","alterations":" EZH2 mutation","tags":["SLC1A5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EZH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ezharmia (valemetostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 141","initiation":"Initiation: 06/11/2021","start_date":" 06/11/2021","primary_txt":" Primary completion: 12/03/2024","primary_completion_date":" 12/03/2024","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-01-24"},{"id":"46a1e98d-dee3-4d71-a1e5-aefae695a396","acronym":"KEYNOTE-F85","url":"https://clinicaltrials.gov/study/NCT06644768","created_at":"2025-02-25T16:02:58.459Z","updated_at":"2025-02-25T16:02:58.459Z","phase":"Phase 1/2","brief_title":"A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations","source_id_and_acronym":"NCT06644768 - KEYNOTE-F85","lead_sponsor":"Daiichi Sankyo","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Ezharmia (valemetostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 137","initiation":"Initiation: 10/30/2024","start_date":" 10/30/2024","primary_txt":" Primary completion: 03/30/2028","primary_completion_date":" 03/30/2028","study_txt":" Completion: 04/30/2030","study_completion_date":" 04/30/2030","last_update_posted":"2024-11-14"},{"id":"b4088fdb-ec50-47ff-acf6-df6ef4b30a62","acronym":"TAZNI","url":"https://clinicaltrials.gov/study/NCT05407441","created_at":"2022-06-07T22:59:09.709Z","updated_at":"2025-02-25T14:17:01.156Z","phase":"Phase 1/2","brief_title":"Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors","source_id_and_acronym":"NCT05407441 - TAZNI","lead_sponsor":"Susan Chi, MD","biomarkers":" SMARCB1","pipe":" | ","alterations":" SMARCA4 mutation","tags":["SMARCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMARCA4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Tazverik (tazemetostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 08/10/2023","start_date":" 08/10/2023","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2029","study_completion_date":" 02/01/2029","last_update_posted":"2024-09-13"},{"id":"7d21338e-ff73-41cf-853f-9516a337a92e","acronym":"FIH","url":"https://clinicaltrials.gov/study/NCT04104776","created_at":"2021-08-13T14:52:51.135Z","updated_at":"2025-02-25T15:43:41.485Z","phase":"Phase 1/2","brief_title":"A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas","source_id_and_acronym":"NCT04104776 - FIH","lead_sponsor":"Constellation Pharmaceuticals","biomarkers":" MSI • ARID1A • BAP1","pipe":" | ","alterations":" MSI-H/dMMR • ARID1A mutation","tags":["MSI • ARID1A • BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • tulmimetostat (DZR123)"],"overall_status":"Recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 09/18/2019","start_date":" 09/18/2019","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-08-02"},{"id":"ad50b74e-df77-4142-938b-467110fb4a75","acronym":"SYMPHONY-1","url":"https://clinicaltrials.gov/study/NCT04224493","created_at":"2023-06-02T17:05:31.313Z","updated_at":"2024-07-02T16:34:26.311Z","phase":"Phase 3","brief_title":"Study of Tazemetostat Versus Placebo When Given in Combination With Lenalidomide and Rituximab in Participants With Relapsed/Refractory Follicular Lymphoma","source_id_and_acronym":"NCT04224493 - SYMPHONY-1","lead_sponsor":"Epizyme, Inc.","biomarkers":" EZH2","pipe":" | ","alterations":" EZH2 mutation","tags":["EZH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EZH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • Tazverik (tazemetostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 612","initiation":"Initiation: 06/11/2020","start_date":" 06/11/2020","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2024-06-13"},{"id":"2bbb09d4-a4c2-44c0-86f9-0f0a553fad4d","acronym":"Mandolin","url":"https://clinicaltrials.gov/study/NCT06068881","created_at":"2023-10-05T16:11:20.119Z","updated_at":"2024-07-02T16:34:59.499Z","phase":"Phase 2","brief_title":"A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an \"EZH2 Gain-of-function\" Genetic Mutation","source_id_and_acronym":"NCT06068881 - Mandolin","lead_sponsor":"Epizyme, Inc.","biomarkers":" EZH2","pipe":" | ","alterations":" EZH2 mutation • EZH2 wild-type","tags":["EZH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EZH2 mutation • EZH2 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tazverik (tazemetostat)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 09/02/2024","start_date":" 09/02/2024","primary_txt":" Primary completion: 09/28/2027","primary_completion_date":" 09/28/2027","study_txt":" Completion: 09/28/2027","study_completion_date":" 09/28/2027","last_update_posted":"2024-06-03"},{"id":"d5547275-acd2-4edc-8fac-11affa680d28","acronym":"CELLO-1","url":"https://clinicaltrials.gov/study/NCT04179864","created_at":"2021-01-18T20:22:59.772Z","updated_at":"2024-07-02T16:34:59.510Z","phase":"Phase 1/2","brief_title":"A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer","source_id_and_acronym":"NCT04179864 - CELLO-1","lead_sponsor":"Epizyme, Inc.","biomarkers":" EZH2","pipe":"","alterations":" ","tags":["EZH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • abiraterone acetate • prednisone • Tazverik (tazemetostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 11/18/2019","start_date":" 11/18/2019","primary_txt":" Primary completion: 06/28/2024","primary_completion_date":" 06/28/2024","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-06-03"},{"id":"f7eb27f3-8b9e-4d94-9852-c62cefd66a29","acronym":"","url":"https://clinicaltrials.gov/study/NCT04388852","created_at":"2021-01-18T21:11:08.040Z","updated_at":"2024-07-02T16:35:03.232Z","phase":"Phase 1","brief_title":"DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers","source_id_and_acronym":"NCT04388852","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • TP53 • PTEN • RB1","pipe":"","alterations":" ","tags":["PD-L1 • TP53 • PTEN • RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • Ezharmia (valemetostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 08/20/2020","start_date":" 08/20/2020","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-16"},{"id":"64c0eae1-673c-4049-a5b1-8479f1fe1ac9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05683171","created_at":"2023-01-13T15:59:24.110Z","updated_at":"2024-07-02T16:35:04.648Z","phase":"Phase 1/2","brief_title":"A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma","source_id_and_acronym":"NCT05683171","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*1*1 • UGT1A1 mutation","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • Ezharmia (valemetostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/19/2023","start_date":" 05/19/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-05-09"},{"id":"a42b730f-7cb0-4a7e-b9c9-5253a2b3eeb8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04390737","created_at":"2022-05-12T19:53:40.351Z","updated_at":"2024-07-02T16:35:04.605Z","phase":"Phase 1/2","brief_title":"Evaluate the Safety and Clinical Activity of HH2853","source_id_and_acronym":"NCT04390737","lead_sponsor":"Haihe Biopharma Co., Ltd.","biomarkers":" ARID1A • BAP1","pipe":" | ","alterations":" ARID1A mutation • BAP1 mutation • EZH2 mutation • SMARCA4 mutation","tags":["ARID1A • BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation • BAP1 mutation • EZH2 mutation • SMARCA4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HH2853"],"overall_status":"Recruiting","enrollment":" Enrollment 254","initiation":"Initiation: 09/08/2020","start_date":" 09/08/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-09"},{"id":"25e24245-9e4c-4767-b5e7-b2e9ba8446f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05983965","created_at":"2023-08-09T14:09:35.762Z","updated_at":"2024-07-02T16:35:05.238Z","phase":"Phase 1","brief_title":"Study of Tazemetostat in Lymphoid Malignancies","source_id_and_acronym":"NCT05983965","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" CD4","pipe":" | ","alterations":" Chr t(11;14) • CCND1 expression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calquence (acalabrutinib) • Tazverik (tazemetostat)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2024-05-08"},{"id":"a5409d19-a682-484b-8074-dbc0380cdead","acronym":"","url":"https://clinicaltrials.gov/study/NCT02601950","created_at":"2021-01-17T17:38:36.460Z","updated_at":"2024-07-02T16:35:07.229Z","phase":"Phase 2","brief_title":"A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma","source_id_and_acronym":"NCT02601950","lead_sponsor":"Epizyme, Inc.","biomarkers":" CD34 • SS18","pipe":" | ","alterations":" SMARCA4 mutation","tags":["CD34 • SS18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMARCA4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tazverik (tazemetostat)"],"overall_status":"Completed","enrollment":" Enrollment 267","initiation":"Initiation: 12/22/2015","start_date":" 12/22/2015","primary_txt":" Primary completion: 02/26/2024","primary_completion_date":" 02/26/2024","study_txt":" Completion: 02/26/2024","study_completion_date":" 02/26/2024","last_update_posted":"2024-04-29"},{"id":"e4a4b657-550e-4739-b71c-fff75613dfbe","acronym":"ETCTN 10500","url":"https://clinicaltrials.gov/study/NCT05627245","created_at":"2022-11-25T15:58:14.707Z","updated_at":"2024-07-02T16:35:09.644Z","phase":"Phase 1","brief_title":"Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment","source_id_and_acronym":"NCT05627245 - ETCTN 10500","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EZH2","pipe":" | ","alterations":" RAS wild-type • EZH2 mutation • EZH2 wild-type","tags":["EZH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type • EZH2 mutation • EZH2 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tazverik (tazemetostat) • Beleodaq (belinostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-04-15"},{"id":"4b00b49c-05e6-4442-a15d-1f3b8ac293cc","acronym":"VALENTINE-PTCL01","url":"https://clinicaltrials.gov/study/NCT04703192","created_at":"2021-01-19T20:51:00.905Z","updated_at":"2024-07-02T16:35:09.833Z","phase":"Phase 2","brief_title":"Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)","source_id_and_acronym":"NCT04703192 - VALENTINE-PTCL01","lead_sponsor":"Daiichi Sankyo","biomarkers":" ALK • CD8","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ezharmia (valemetostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 148","initiation":"Initiation: 06/03/2021","start_date":" 06/03/2021","primary_txt":" Primary completion: 05/10/2023","primary_completion_date":" 05/10/2023","study_txt":" Completion: 04/30/2028","study_completion_date":" 04/30/2028","last_update_posted":"2024-04-12"},{"id":"d34b2972-2631-4419-9b42-d2369ac4edd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04225429","created_at":"2021-01-18T20:34:10.242Z","updated_at":"2024-07-02T16:35:13.248Z","phase":"","brief_title":"Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma","source_id_and_acronym":"NCT04225429","lead_sponsor":"Epizyme, Inc.","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tazverik (tazemetostat)"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2024-03-22"},{"id":"2081d67d-68ba-4944-9cbd-65ba437e972d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05627232","created_at":"2024-01-05T19:19:11.024Z","updated_at":"2024-07-02T16:35:24.396Z","phase":"Phase 1","brief_title":"Palbociclib or Tazemetostat in Combination With CPX-351 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05627232","lead_sponsor":"Thomas Jefferson University","biomarkers":" CASP3 • ANXA5","pipe":"","alterations":" ","tags":["CASP3 • ANXA5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Vyxeos (cytarabine/daunorubicin liposomal formulation) • Tazverik (tazemetostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 08/28/2023","start_date":" 08/28/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-01-05"},{"id":"4da35385-bc68-447a-9f55-d20c695bb000","acronym":"","url":"https://clinicaltrials.gov/study/NCT04407741","created_at":"2021-01-18T21:15:24.844Z","updated_at":"2024-07-02T16:35:26.534Z","phase":"Phase 1/2","brief_title":"Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas","source_id_and_acronym":"NCT04407741","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" EGFR • BRAF • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e retlirafusp alfa (SHR-1701) • zeprumetostat (SHR-2554)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-12-12"},{"id":"2dd99279-9ac9-4f3f-9024-0d203f7d34e4","acronym":"NRG-GY014","url":"https://clinicaltrials.gov/study/NCT03348631","created_at":"2021-01-18T16:32:10.163Z","updated_at":"2024-07-02T16:35:29.997Z","phase":"Phase 2","brief_title":"Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer","source_id_and_acronym":"NCT03348631 - NRG-GY014","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ARID1A","pipe":" | ","alterations":" MSI-H/dMMR • ARID1A mutation","tags":["ARID1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tazverik (tazemetostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 05/01/2019","start_date":" 05/01/2019","primary_txt":" Primary completion: 04/14/2023","primary_completion_date":" 04/14/2023","study_txt":" Completion: 09/21/2024","study_completion_date":" 09/21/2024","last_update_posted":"2023-11-08"},{"id":"629d3e43-0e85-4938-b444-ed8c4cd850d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03028103","created_at":"2021-01-18T14:54:14.823Z","updated_at":"2024-07-02T16:35:44.743Z","phase":"Phase 1","brief_title":"Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients","source_id_and_acronym":"NCT03028103","lead_sponsor":"Epizyme, Inc.","biomarkers":" SLC1A5","pipe":"","alterations":" ","tags":["SLC1A5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tazverik (tazemetostat)"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 03/27/2017","start_date":" 03/27/2017","primary_txt":" Primary completion: 10/31/2019","primary_completion_date":" 10/31/2019","study_txt":" Completion: 11/29/2019","study_completion_date":" 11/29/2019","last_update_posted":"2023-06-26"},{"id":"afa91b8a-c52c-483b-b37d-dc401dac8395","acronym":"","url":"https://clinicaltrials.gov/study/NCT05023655","created_at":"2021-08-26T12:53:15.117Z","updated_at":"2024-07-02T16:35:50.284Z","phase":"Phase 2","brief_title":"Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation","source_id_and_acronym":"NCT05023655","lead_sponsor":"Prisma Health-Upstate","biomarkers":" ARID1A","pipe":" | ","alterations":" ARID1A mutation","tags":["ARID1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tazverik (tazemetostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/06/2022","start_date":" 01/06/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2023-04-18"}]